Selective Class II HDAC Inhibitors for Autoimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HDAC inhibitors are non-selective, affecting all HDAC isoforms, which can lead to unwanted side effects and reduced efficacy in treating specific diseases associated with abnormal cell proliferation and immune regulation.
Innovation Solution
Development of a compound according to Formula (Ia) and (Ib) that selectively inhibits Class II HDAC activity, specifically targeting HDAC9 or HDAC7 or HDAC6, to modulate autoimmune diseases and enhance Treg activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective HDAC inhibitors are used, then HDAC activity is inhibited across all isoforms, but unwanted side effects increase and efficacy for specific diseases is reduced
Solution Approach 1:
The patent applies local quality by designing HDAC inhibitors with specific molecular structures ( Formula I compounds) that target particular HDAC isoforms (Class II HDACs: HDAC4, HDAC5, HDAC6, HDAC7, HDAC9) rather than inhibiting all HDAC isoforms non-selectively. This selective inhibition allows beneficial effects in specific disease contexts while avoiding harmful side effects associated with broad-spectrum inhibition.
2Reliability
If selective Class II HDAC inhibitors are developed, then disease-specific efficacy is improved, but compound complexity increases
Solution Approach 1:
The patent employs parameter changes by systematically varying molecular parameters (substituents R1-R6, n values, Z groups) in the core scaffold structure to optimize selectivity for Class II HDACs. By adjusting these parameters, the compounds achieve disease-specific efficacy while maintaining manageable structural complexity through a unified chemical series approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The selective inhibition of Class II HDACs, such as HDAC9 or HDAC7 or HDAC6, enhances Treg suppression and expansion, potentially treating autoimmune diseases, cancer, and other conditions like colitis and cardiac allograft survival with reduced side effects.
Implementation Method 1
HDAC inhibitors and their use in the treatment of cellular proliferative diseases, including cancer, neurodegenerative diseases, schizophrenia and stroke
Implementation Method 2
Histone deacetylases (HDACs) catalyze the deacetylation of histone and non-histone proteins
Data Source
AI summary
Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.